Mean Residence Time as Estimated from Cropped and Truncated Moments

 

 Buy Article Permissions and Reprints

Abstract

For non-compartmental concentration-time curve analysis the mean residence time (MRT) is usually estimated using numerical summation and log-linear extrapolation. However, when the initial ear of the curve is cropped and the terminal tail is truncated the MRT can be estimated without extrapolation using numerical methods alone. This paper is to evaluate the error of the cut MRT derived from cropped and truncated moments. The cut MRT is estimated from exclusively measured but non extrapolated concentrations. Mono-exponential kinetics after single intravenous dosing is considered.

Two conditions define the acceptable cutoff error of 5% or less: For cropping, the first concentration must be measured immediately after dosing at time t₁ that is 0.14 times the elimination half-life (t₁ = 0.14 × T_1/2). For truncation, the concentration must be observed for a near 2 log decline period (t_n) or, exactly, 6.51 times the elimination half-life (t_n = 6.51 × T_1/2). From data of previous studies, the MRT truncation error of only 0.39% for methylprednisolone (CAS 2375-3-3) was estimated with an observation period of 10 times one half-life (24 h = 10.4 × 2.3 h) but 4.3% for cyclosporin (CAS 59865-13-3), with an investigation interval of only 2 times one half-life (12 h = 2 × 6.1 h). For the complex kinetics of raloxifene (CAS 82640-04-8) it was seen that the cropping and truncation errors are non additive.

Conclusion:

If a reliable extrapolation is impossible, the cut MRT can be estimated only from measured concentrations. However, the cropping and the truncation maneuvers should be considered simultaneously to counterbalance the cutoff errors.

• References

• 1 Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008; Dec 25 (12) 2869-77
  CrossrefPubMedGoogle Scholar
• 2 Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978; Dec 6 (6) 547-58
  CrossrefPubMedGoogle Scholar
• 3 Dost FH. [A simple statistical dosage metabolism law.]. Klin Wochenschr. Jul 15 36 (14) 655-7
  PubMedGoogle Scholar
• 4 Dettli L. The kidney in pre-clinical and clinical pharmacokinetics. Jpn J Clin Pharmacol Ther. 1984; Mar 15 (1) 241-54
  CrossrefPubMedGoogle Scholar
• 5 Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia: Lea & Febiger; 1989: 482
  Google Scholar
• 6 Powers JD. Statistical considerations in pharmacokinetic study design. Clin Pharmacokinet. 1993; May 24 (5) 380-7 Review
  CrossrefPubMedGoogle Scholar
• 7 Cheung BW, Cartier LL, Russlie HQ, Sawchuk RJ. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies. Fundam Clin Pharmacol. 2005; Jun 19 (3) 347-54
  CrossrefPubMedGoogle Scholar
• 8 Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980; Oct 8 (5) 509-34
  CrossrefPubMedGoogle Scholar
• 9 Ducharme J, Varin F, Bevan DR, Donati F. Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters. Clin Pharmacokinet. 1993; Jun 24 (6) 507-18
  CrossrefPubMedGoogle Scholar
• 10 Kaniwa N, Ogata H, Aoyagi N, Takeda Y, Uchiyama M. Power analyses of moment analysis parameter in bioequivalence tests. J Pharm Sci. 1989; Dec 78 (12) 1020-4
  CrossrefPubMedGoogle Scholar
• 11 Kong AN, Jusko WJ. Definitions and applications of mean transit and residence times in reference to the two-compartment mammillary plasma clearance model. J Pharm Sci. 1988; Feb 77 (2) 157-65
  CrossrefPubMedGoogle Scholar
• 12 Yates JW, Arundel PA. On the volume of distribution at steady state and its relationship with two-compartmental models. J Pharm Sci. 2008; Jan 97 (1) 111-22
  CrossrefPubMedGoogle Scholar
• 13 Uhl A, Czock D, Boehm BO, Zellner D, Mertz A, Keller F. Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. J Clin Pharm Ther. 2002; Aug 27 (4) 281-7
  CrossrefPubMedGoogle Scholar
• 14 Keller F, Kunzendorf U, Walz G, Schwarz A, Offermann G. Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. Int J Clin Pharmacol Ther Toxicol. 1990; Apr 28 (4) 167-75
  PubMedGoogle Scholar
• 15 Czock D, Keller F, Heringa M, Rasche FM. Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol. 2005; Apr 59 (4) 479-82
  CrossrefPubMedGoogle Scholar
• 16 Niedzwiecki D, Simonoff JS. Estimation and inference in pharmacokinetic models: the effectiveness of model reformulation and resampling methods for functions of parameters. J Pharmacokinet Biopharm. 1990; Aug 18 (4) 361-77
  CrossrefPubMedGoogle Scholar
• 17 Erkent U, Koytchev R. The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. Arzneimittelforschung. 2008; 58 (5) 255-8
  Article in Thieme ConnectPubMedGoogle Scholar
• 18 European Medicines Agency EMEA. Clinical Pharmacology and Pharmacokinetics. Pharmacokinetic Studies in Man. Reference number 3CC3A. Oct 1998. p. 105. http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm (accessed 17. Dec. 2008)
  PubMed